These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16335261)

  • 1. [Possibilities of medical treatment in acromegaly].
    Cáp J; Nemecek S; Rezácová M; Cerman J
    Cas Lek Cesk; 2005; 144 Suppl 3():33-4, 36-7. PubMed ID: 16335261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapy for acromegaly.
    Newman CB
    Endocrinol Metab Clin North Am; 1999 Mar; 28(1):171-90. PubMed ID: 10207690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acromegaly - evolving strategies.
    Popovic V
    Pediatr Endocrinol Rev; 2004 Aug; 1 Suppl 3():496-500. PubMed ID: 16444181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment in acromegaly.
    Paisley AN; Trainer PJ
    Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists.
    Howlett TA; Willis D; Walker G; Wass JA; Trainer PJ;
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):689-99. PubMed ID: 23574573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
    Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
    Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of prolactin and growth hormone-secreting pituitary tumors].
    Jadresic A
    Rev Med Chil; 1997 Nov; 125(11):1383-8. PubMed ID: 9609063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological approach to the treatment of acromegaly.
    Ezzat S
    Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: Primary medical therapy of acromegaly.
    Katznelson L
    Nat Clin Pract Endocrinol Metab; 2006 Feb; 2(2):109-17; quiz following 117. PubMed ID: 16932265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective are current therapies for acromegaly?
    Freda PU
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogs in medical treatment of acromegaly.
    Racine MS; Barkan AL
    Endocrine; 2003 Apr; 20(3):271-8. PubMed ID: 12721507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of acromegaly.
    Díez JJ; Iglesias P
    Expert Opin Pharmacother; 2000 Jul; 1(5):991-1006. PubMed ID: 11249504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New formulations and approaches in the medical treatment of acromegaly.
    Debono M; Newell-Price J
    Curr Opin Endocrinol Diabetes Obes; 2010 Aug; 17(4):350-5. PubMed ID: 20502324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.